

Susanna Naggie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1303188/publications.pdf>

Version: 2024-02-01

64
papers

2,652
citations

201674

27
h-index

189892

50
g-index

66
all docs

66
docs citations

66
times ranked

3910
citing authors

#	ARTICLE	IF	CITATIONS
1	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 256-268.	4.4	34
2	A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 7, 307-317.	8.1	39
3	COVID-19 Trials: Who Participates and Who Benefits?. <i>Southern Medical Journal</i> , 2022, 115, 256-261.	0.7	2
4	COVID-19â€™ Lessons Learned and Questions Remaining. <i>Clinical Infectious Diseases</i> , 2021, 72, 2225-2240.	5.8	54
5	The Prevalence and Burden of Non-AIDS Comorbidities Among Women Living With or at Risk for Human Immunodeficiency Virus Infection in the United States. <i>Clinical Infectious Diseases</i> , 2021, 72, 1301-1311.	5.8	46
6	New Therapeutics for Hepatitis B: The Road to Cure. <i>Annual Review of Medicine</i> , 2021, 72, 93-105.	12.2	38
7	Incident Non-AIDS Comorbidity Burden Among Women With or at Risk for Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, e2059-e2069.	5.8	9
8	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	12.8	194
9	Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform. <i>Contemporary Clinical Trials</i> , 2021, 109, 106525.	1.8	3
10	Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a realâ€w world study from a multicentre VA cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 630-636.	2.0	2
11	A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). <i>Contemporary Clinical Trials Communications</i> , 2021, 24, 100851.	1.1	4
12	Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 1-21.	4.5	58
13	A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. <i>Hepatology</i> , 2020, 71, 1894-1909.	7.3	24
14	Cardiovascular Disease Risk Management in Persons With HIV: Does Clinician Specialty Matter?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa361.	0.9	6
15	Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection. <i>Journal of Infectious Diseases</i> , 2020, 222, 2012-2020.	4.0	5
16	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination. <i>Journal of Infectious Diseases</i> , 2020, 222, S741-S744.	4.0	1
17	Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800006.	1.6	1
18	Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3394-3401.	2.3	6

#	ARTICLE	IF	CITATIONS
19	Management of Hepatitis C in 2019. JAMA - Journal of the American Medical Association, 2019, 322, 355.	7.4	9
20	Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?. Hepatology Communications, 2019, 3, 453-455.	4.3	2
21	Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clinical Infectious Diseases, 2019, 69, 514-522.	5.8	20
22	2549. Variance Between Clinicians and Guidelines in Management of HIV/HCV Coinfection. Open Forum Infectious Diseases, 2019, 6, S886-S886.	0.9	0
23	301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections. Open Forum Infectious Diseases, 2019, 6, S162-S162.	0.9	0
24	Hepatitis C Behind and Beyond Bars. North Carolina Medical Journal, 2019, 80, 352-355.	0.2	1
25	Treating HCV Infection: It Doesn't Get Much Better Than This. Topics in Antiviral Medicine, 2019, 26, 104-108.	0.1	4
26	The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. Open Forum Infectious Diseases, 2018, 5, ofx267.	0.9	7
27	Metabolites predict cardiovascular disease events in persons living with HIV: a pilot caseâ€“control study. Metabolomics, 2018, 14, 1.	3.0	11
28	Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection. Open Forum Infectious Diseases, 2018, 5, ofx264.	0.9	42
29	Hepatitis C Virus Elimination in the Human Immunodeficiency Virusâ€“Coinfected Population. Infectious Disease Clinics of North America, 2018, 32, 407-423.	5.1	12
30	The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Contemporary Clinical Trials, 2018, 72, 73-85.	1.8	7
31	Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. Journal of Cardiac Failure, 2018, 24, 496-503.	1.7	22
32	Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection. Open Forum Infectious Diseases, 2018, 5, ofy138.	0.9	2
33	Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs, 2017, 77, 131-144.	10.9	52
34	Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clinical Infectious Diseases, 2017, 65, 6-12.	5.8	133
35	Benefits of Direct-Acting Antivirals for Hepatitis C. Annals of Internal Medicine, 2017, 167, 812.	3.9	13
36	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clinical Infectious Diseases, 2017, 65, 1773-1775.	5.8	11

#	ARTICLE	IF	CITATIONS
37	Comments on cochrane review on direct-acting antivirals for hepatitis C. <i>Hepatology</i> , 2017, 66, 1016-1019.	7.3	3
38	Retreatment Options Following HCV Direct-Acting Antiviral Failure. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 389-402.	1.9	14
39	Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. <i>Annual Review of Medicine</i> , 2017, 68, 345-358.	12.2	57
40	Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. <i>Clinical Infectious Diseases</i> , 2017, 64, 1035-1042.	5.8	42
41	Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw258.	0.9	8
42	Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfecting patients with incomplete hepatitis B virus viral suppression. <i>Hepatology</i> , 2016, 64, 999-1000.	7.3	3
43	Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 407-413.	5.8	49
44	Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw173.	0.9	8
45	Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 528-531.	5.8	13
46	Successes and Challenges on the Road to Cure Hepatitis C. <i>PLoS Pathogens</i> , 2015, 11, e1004854.	4.7	36
47	Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv066.	0.9	0
48	Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2166-2172.	4.4	40
49	Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015, 373, 705-713.	27.0	432
50	Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014. <i>Current HIV/AIDS Reports</i> , 2013, 10, 408-419.	3.1	17
51	Health Care Utilization in HIV-Infected Patients: Assessing the Burden of Hepatitis C Virus Coinfection. <i>AIDS Patient Care and STDs</i> , 2012, 26, 541-545.	2.5	22
52	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383.	4.0	31
53	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response. <i>Hepatology</i> , 2012, 56, 444-454.	7.3	61
54	An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1083-1091.	2.3	27

#	ARTICLE	IF	CITATIONS
55	Management of hepatitis C virus infection: the basics. <i>Topics in Antiviral Medicine</i> , 2012, 20, 154-61.	0.1	15
56	A Case-control Study of Community-associated <i>Clostridium difficile</i> Infection: No Role for Proton Pump Inhibitors. <i>American Journal of Medicine</i> , 2011, 124, 276.e1-276.e7.	1.5	84
57	Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. <i>Hepatology</i> , 2011, 53, 389-395.	7.3	67
58	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2010, 24, F23-F29.	2.2	184
59	Risk Factors for and Estimated Incidence of Community-associated <i>Clostridium difficile</i> Infection, North Carolina, USA. <i>Emerging Infectious Diseases</i> , 2010, 16, 197-204.	4.3	186
60	Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1094-1099.	3.0	30
61	Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2063-2069.	3.0	38
62	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction. <i>Gastroenterology</i> , 2010, 139, 1181-1189.e2.	1.3	171
63	Molds: Hyalohyphomycosis, Phaeohyphomycosis, and Zygomycosis. <i>Clinics in Chest Medicine</i> , 2009, 30, 337-353.	2.1	67
64	Assessment of <i>Clostridium difficile</i> Associated Disease Surveillance Definitions, North Carolina, 2005. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 197-202.	1.8	51